Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
THE SO WHAT
A $160M IPO for a late-stage sleep apnea drug developer is another data point that public markets will still fund focused, single-asset biotechs. Healthtech and AI-in-drug-discovery founders should read this as: capital is there if you can show a clean regulatory path and a tightly defined indication, not just a platform story.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureUK pension providers in talks for £1bn Scale-Up Fund
If £1bn of UK pension money gets earmarked for “scale-up” rather than late-stage buyouts, the bar for domestic growth equity rounds moves. Founders in the UK should be tightening governance and reporting now — pension capital comes with institutional expectations and slower, more process-heavy decision cycles.
Startups & VentureInsight Partners And Glilot Capital Co-Lead $20M Investment In Way Security To Reinvent IAM Operations
A $20M round into IAM operations tooling reflects how identity sprawl — across SaaS, cloud, and now AI services — has become unmanageable with first-gen IAM suites alone. CISOs should be budgeting for a second layer of orchestration and observability on top of existing identity stacks rather than assuming the incumbent vendor will catch up.
Startups & VentureHillhouse-Backed Tablespace Said to File $350 Million India IPO
A $350M IPO for an Indian managed workspace provider suggests public markets are willing to underwrite flexible office as an operating platform, not just a real estate trade. Founders in India’s proptech and workspace stack should be thinking about how their software and services can plug into — or compete with — these scaled operators as they gain cheaper capital.
Startups & VentureMultiverse Computing Announces Series C Fundraising Targeting up to $570 Million
A targeted $570 million Series C at a $1.7 billion pre-money for an ‘efficient AI’ player shows real capital is lining up behind cost-optimized LLMs, not just bigger ones. If your AI unit economics depend on hyperscaler pricing, you now have to assume specialized efficiency vendors will undercut you on inference and training costs.